In this webinar, Dr. Lina Abi Mosleh will introduce the Ayass Hereditary Cancer Risk Assessment test offered by Ayass Bioscience. This test targets 276 SNPs across 103 genes which have been previously linked to a predisposition to common and rare
forms of cancer such as leukemia, ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, lung cancer and skin cancer.
Dr. Lina Abi Mosleh will also discuss how Ayass performs this test on the cost-effective and rapid MassARRAY system. By leveraging MALDI-TOF technology, Ayass is able to screen for the most impactful variants in a cost and time-efficient manner.
Dr. Mosleh will discuss why Ayass choose to perform this test on a targeted technology rather than employing larger gene panels typically run on Next Generation Sequencing Technology.
- Learn about the importance of genetic inherited cancer risk testing
- Learn how cancer risk testing can be achived using a rapid, cost-effective workflow (MassARRAY)
- Learn about the trade-offs between broad-based sequencing vs targeted approaches
Lina Abi Mosleh, Ph.D
Lina is the Vice President and Principal Scientist at Ayass Bioscience, LLC with the responsibility to oversee, manage, and lead daily operations in both the clinical and research laboratories. Prior to joining Ayass Bioscience, her career was
focused on basic science research in academic institutions where she served as a faculty member. The opportunity presented at Ayass Bioscience allowed her to utilize her skills and dive into the world of translational research by bridging
science to patient care. She is involved in the design, development, and validation of high complexity molecular testing from next generation sequencing to array-based genotyping assays. She is also part of a research team that develops aptamers
for diagnostic and therapeutic applications, utilizes nanotechnology for diagnostics applications, and identifies and clinically validates new biomarkers for autoimmune disease. One of the company’s most recent projects involved the
development of a Thrombosis Risk Assessment Tool called “MoNet”. MoNet is an advanced biological tool that uses CAI (Cognitive Artificial Intelligence) to collect and analyze data from hundreds of molecular tests conducted on thousands
of patients at Ayass Bioscience to identify clinical associations between biomarkers and generate a prediction score for an individual’s risk of thrombosis.
Lina earned her Bachelor’s and Master’s in Cell Biology at the American University of Beirut in Lebanon. Upon moving to the U.S., Lina received her Ph.D. in Molecular Genetics and Biochemistry at the University of Texas Southwestern
Medical Center at Dallas in the laboratory of Nobel laureates Drs. Michael S. Brown and Joseph L Goldstein.
Cost: No Cost!